Affiliation:
1. College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China
Abstract
Abstract
Candida auris is a widely distributed, highly lethal, multidrug-resistant fungal pathogen. It was first identified in 2009 when it was isolated from fluid drained from the external ear canal of a patient in Japan. Since then, it has caused infectious outbreaks in over 45 countries, with mortality rates approaching 60%. Drug resistance is common in this species, with a large proportion of isolates displaying fluconazole resistance and nearly half are resistant to two or more antifungal drugs. In this review, we describe the drug resistance mechanism of C. auris and potential small-molecule drugs for treating C. auris infection. Among these antifungal agents, rezafungin was approved by the US Food and Drug Administration (FDA) for the treatment of candidemia and invasive candidiasis on March 22, 2023. Ibrexafungerp and fosmanogepix have entered phase III clinical trials.
Funder
National Key Research and Development Program of China
National Natural Science Foundation of China
Key Research and Development Program of Zhejiang Province
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,General Medicine
Reference51 articles.
1. On the origins of a species: what might explain the rise of Candida auris;Jackson;J Fungi (Basel),2019
2. Candida auris: a review of recommendations for detection and control in healthcare settings;Caceres;J Fungi (Basel),2019
3. Candida auris: another frontier in the battle against antimicrobial resistance;Tina;BMJ,2023
4. Insights into the unique nature of the East Asian clade of the emerging pathogenic yeast Candida auris;Rory;J Clin Microbiol,2019
5. Fungal priority pathogen list to guide research, development and public health action;WHO,2022